Gain-of-function mutations in NFE2L2 and inactivating KEAP1 mutations are the most frequent NRF2 activation mechanisms observed in breast, gallbladder, and lung tumors, among other cancer types [19–23]. Here, NFE2L2 is linked to cancer.